Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
In the absence of other risk factors, do you treat the regional lymph nodes in triple negative breast cancer?
Or for that matter, offer PMRT on the basis of a patient having triple negative disease?
Answer from: Radiation Oncologist at Community Practice
At present I don't, but once Canadian and EORTC studies are published with full details available, it may change practice patterns.
Sign In
or
Register
to read more
415
Related Questions
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
Is ultrahypofractionation appropriate for a B51 candidate receiving breast-only radiation?
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
Does micropapillary subtype for a G1-2 DCIS affect your radiation treatment recommendations?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
How, if at all, does your practice differ between male and female breast cancer patients with respect to the use of bolus?
How do you treat a patient with early-stage breast cancer s/p lumpectomy and oncoplastic reconstruction with a positive margin, when re-excision is not feasible?
Would you offer PMRT to a patient with potential metastatic disease?
Is it appropriate to consider ultra-hypofractionation for phyllodes tumors of the breast when adjuvant radiotherapy is indicated?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?